Drugs / MLN2704
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00052000 | Nov 2002 → ? | prostate cancer | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00070837 | Oct 2003 → Oct 2004 | prostate neoplasm | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MLN2704 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00052000 ↗ |
| Known as | MLN-591DM1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109556 ↗ |
| Known as | MLN591 | “MLN2704 (DM1 conjugated monoclonal antibody MLN591)” NCT00070837 ↗1“MLN2704 (DM1 conjugated monoclonal antibody MLN591)” NCT00052000 ↗ |
| Modality | Monoclonal antibody | “conjugated monoclonal antibody MLN591” NCT00052000 ↗ |
| Target | FOLH1 | “Glutamate carboxypeptidase II binding agent” CHEMBL2109556 ↗ |